Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 105256, 9 pages
http://dx.doi.org/10.1155/2015/105256
Review Article

Updates on Nutraceutical Sleep Therapeutics and Investigational Research

1University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
2Middlebury College, 14 Old Chapel Road, Burlington, VT 05753, USA
3Veterans Administration, 400 Fort Hill Avenue, Canandaigua, NY 14424, USA

Received 26 May 2015; Accepted 1 July 2015

Academic Editor: Karen Nieber

Copyright © 2015 Michael Yurcheshen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. M. Altevogt and H. R. Colten, Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem, National Academies Press, Washington, DC, USA, 2006.
  2. J. W. Daly, I. Hide, C. E. Muller, and M. Shamim, “Caffeine analogs: structure-activity relationships at adenosine receptors,” Pharmacology, vol. 42, no. 6, pp. 309–321, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. National Center for Biotechnology Information, PubChem Compound Database; CID = 2519, March 2015, http://pubchem.ncbi.nlm.nih.gov/compound/caffeine#section=Top.
  4. K. W. Andrews, A. Schweitzer, C. Zhao et al., “The caffeine contents of dietary supplements commonly purchased in the US: analysis of 53 products with caffeine-containing ingredients,” Analytical and Bioanalytical Chemistry, vol. 389, no. 1, pp. 231–239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Karadsheh, P. Kussie, and D. S. Linthicum, “Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives,” Toxicology Letters, vol. 55, no. 3, pp. 335–342, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Brezová, A. Šlebodová, and A. Staško, “Coffee as a source of antioxidants: an EPR study,” Food Chemistry, vol. 114, no. 3, pp. 859–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Ker, P. J. Edwards, L. M. Felix, K. Blackhall, and I. Roberts, “Caffeine for the prevention of injuries and errors in shift workers,” The Cochrane Database of Systematic Reviews, 2010. View at Publisher · View at Google Scholar
  8. M. Beaumont, D. Batéjat, C. Piérard et al., “Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel,” Journal of Applied Physiology, vol. 96, no. 1, pp. 50–58, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. L. N. Sharwood, J. Elkington, L. Meuleners, R. Ivers, S. Boufous, and M. Stevenson, “Use of caffeinated substances and risk of crashes in long distance drivers of commercial vehicles: case-control study,” British Medical Journal, vol. 346, no. 7900, Article ID f1140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Caldeira, C. Martins, L. B. Alves, H. Pereira, J. J. Ferreira, and J. Costa, “Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies,” Heart, vol. 99, no. 19, pp. 1383–1389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S.-M. Lee, N.-K. Choi, B.-C. Lee, K.-H. Cho, B.-W. Yoon, and B.-J. Park, “Caffeine-containing medicines increase the risk of hemorrhagic stroke,” Stroke, vol. 44, no. 8, pp. 2139–2143, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Lubin, E. Ron, Y. Wax, M. Black, M. Funaro, and A. Shitrit, “A case-control study of caffeine and methylxanthines in benign breast disease,” Journal of the American Medical Association, vol. 253, no. 16, pp. 2388–2392, 1985. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Singh, Z. Khanam, N. Misra, and M. K. Srivastava, “Chamomile (Matricaria chamomilla L.): an overview,” Pharmacognosy Reviews, vol. 5, no. 9, pp. 82–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Safayhi, J. Sabieraj, E.-R. Sailer, and H. P. T. Ammon, “Chamazulene: an antioxidant-type inhibitor of leukotriene B4 formation,” Planta Medica, vol. 60, no. 5, pp. 410–413, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Schilcher, Die Kamille: Handbuch für Ärzte, Apotheker und andere Naturwissenschaftler, Wissenschaftliche Verlagsgesellschaft, 1987.
  16. P. Zanoli, R. Avallone, and M. Baraldi, “Behavioral characterisation of the flavonoids apigenin and chrysin,” Fitoterapia, vol. 71, supplement 1, pp. S117–S123, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. E. L. Campbell, M. Chebib, and G. A. R. Johnston, “The dietary flavonoids apigenin and (−)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABAA receptors,” Biochemical Pharmacology, vol. 68, no. 8, pp. 1631–1638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Zick, B. D. Wright, A. Sen, and J. T. Arnedt, “Preliminary examination of the efficacy and safety of a standardized chamomile extract for chronic primary insomnia: a randomized placebo-controlled pilot study,” BMC Complementary and Alternative Medicine, vol. 11, article 78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. US National Library of Medicine, ClinicalTrials.gov, 2015, https://clinicaltrials.gov/.
  20. R. J. G. Rycroft, “Recurrent facial dermatitis from chamomile tea,” Contact Dermatitis, vol. 48, no. 4, p. 229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Giordano-Labadie, H. P. Schwarze, and J. Bazex, “Allergic contact dermatitis from camomile used in phytotherapy,” Contact Dermatitis, vol. 42, no. 4, p. 247, 2000. View at Google Scholar · View at Scopus
  22. F. Facchinetti, G. Pedrielli, G. Benoni et al., “Herbal supplements in pregnancy: unexpected results from a multicentre study,” Human Reproduction, vol. 27, no. 11, pp. 3161–3167, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Traustadottir, S. S. Davies, A. A. Stock et al., “Proprietary tart cherry juice blend decreases oxidative stress in healthy older adults,” in Free Radical Biology and Medicine, p. S91, Elsevier Science, 2008. View at Google Scholar
  24. G. Howatson, M. P. McHugh, J. A. Hill et al., “Influence of tart cherry juice on indices of recovery following marathon running,” Scandinavian Journal of Medicine and Science in Sports, vol. 20, no. 6, pp. 843–852, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Kelley, R. Rasooly, R. A. Jacob, A. A. Kader, and B. E. Mackey, “Consumption of bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and women,” Journal of Nutrition, vol. 136, no. 4, pp. 981–986, 2006. View at Google Scholar · View at Scopus
  26. J. L. Bowtell, D. P. Sumners, A. Dyer, P. Fox, and K. N. Mileva, “Montmorency cherry juice reduces muscle damage caused by intensive strength exercise,” Medicine and Science in Sports and Exercise, vol. 43, no. 8, pp. 1544–1551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. S. Kuehl, E. T. Perrier, D. L. Elliot, and J. C. Chesnutt, “Efficacy of tart cherry juice in reducing muscle pain during running: a randomized controlled trial,” Journal of the International Society of Sports Nutrition, vol. 7, article 17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. A. J. Connolly, M. P. McHugh, and O. I. Padilla-Zakour, “Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage,” British Journal of Sports Medicine, vol. 40, no. 8, pp. 679–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. D.-O. Kim, H. J. Heo, Y. J. Kim, H. S. Yang, and C. Y. Lee, “Sweet and sour cherry phenolics and their protective effects on neuronal cells,” Journal of Agricultural and Food Chemistry, vol. 53, no. 26, pp. 9921–9927, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Wang, M. G. Nair, G. M. Strasburg et al., “Antioxidant and antiinflammatory activities of anthocyanins and their aglycon, cyanidin, from tart cherries,” Journal of Natural Products, vol. 62, no. 2, pp. 294–296, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Wang, M. G. Nair, A. F. Iezzon, G. M. Strasburg, A. M. Booren, and J. I. Gray, “Quantification and characterization of anthocyanins in Balaton tart cherries,” Journal of Agricultural and Food Chemistry, vol. 45, no. 7, pp. 2556–2560, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Burkhardt, D. X. Tan, L. C. Manchester, R. Hardeland, and R. J. Reiter, “Detection and quantification of the antioxidant melatonin in Montmorency and Balaton tart cherries (Prunus cerasus),” Journal of Agricultural and Food Chemistry, vol. 49, no. 10, pp. 4898–4902, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. M. R. Opp, “Cytokines and sleep: the first hundred years,” Brain, Behavior, and Immunity, vol. 18, no. 4, pp. 295–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Howatson, P. G. Bell, J. Tallent, B. Middleton, M. P. McHugh, and J. Ellis, “Effect of tart cherry juice (Prunus cerasus) on melatonin levels and enhanced sleep quality,” European Journal of Nutrition, vol. 51, no. 8, pp. 909–916, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Garrido, S. D. Paredes, J. Cubero et al., “Jerte valley cherry-enriched diets improve nocturnal rest and increase 6-sulfatoxymelatonin and total antioxidant capacity in the urine of middle-aged and elderly humans,” Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, vol. 65, no. 9, pp. 909–914, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. W. R. Pigeon, M. Carr, C. Gorman, and M. L. Perlis, “Effects of a tart cherry juice beverage on the sleep of older adults with insomnia: a pilot study,” Journal of Medicinal Food, vol. 13, no. 3, pp. 579–583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. N. Buscemi, B. Vandermeer, N. Hooton et al., “The efficacy and safety of exogenous melatonin for primary sleep disorders: a meta-analysis,” Journal of General Internal Medicine, vol. 20, no. 12, pp. 1151–1158, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. I. M. Van Geijlswijk, H. P. L. M. Korzilius, and M. G. Smits, “The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis,” Sleep, vol. 33, no. 12, pp. 1605–1614, 2010. View at Google Scholar · View at Scopus
  39. J. B. Fourtillan, A. M. Brisson, P. Gobin, I. Ingrand, J. P. Decourt, and J. Girault, “Bioavailability of melatonin in humans after day-time administration of D7 melatonin,” Biopharmaceutics and Drug Disposition, vol. 21, no. 1, pp. 15–22, 2000. View at Google Scholar · View at Scopus
  40. A. Rowe, R. Narlawar, P. W. Groundwater, and I. Ramzan, “Kavalactone pharmacophores for major cellular drug targets,” Mini-Reviews in Medicinal Chemistry, vol. 11, no. 1, pp. 79–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. H. Pittler and E. Ernst, “Kava extract versus placebo for treating anxiety,” Cochrane Database of Systematic Reviews, vol. 1, 2003. View at Google Scholar
  42. R. Tsutsui, K. Shinomiya, Y. Takeda, Y. Obara, Y. Kitamura, and C. Kamei, “Hypnotic and sleep quality-enhancing properties of kavain in sleep-disturbed rats,” Journal of Pharmacological Sciences, vol. 111, no. 3, pp. 293–298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Lehrl, “Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders: results of a multicenter, randomized, placebo-controlled, double-blind clinical trial,” Journal of Affective Disorders, vol. 78, pp. 101–110, 2004. View at Publisher · View at Google Scholar
  44. R. Teschke, C. Frenzel, X. Glass, J. Schulze, and A. Eickhoff, “Herbal hepatotoxicity: a critical review,” British Journal of Clinical Pharmacology, vol. 75, no. 3, pp. 630–636, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Teschke and J. Schulze, “Risk of kava hepatotoxicity and the FDA consumer advisory,” The Journal of the American Medical Association, vol. 304, no. 19, pp. 2174–2175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Robinson, W. F. Bergfeld, D. V. Belsito et al., “Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract,” International Journal of Toxicology, vol. 28, no. 6, pp. 175S–188S, 2009. View at Google Scholar · View at Scopus
  47. B. Y. Silber and J. A. J. Schmitt, “Effects of tryptophan loading on human cognition, mood, and sleep,” Neuroscience and Biobehavioral Reviews, vol. 34, no. 3, pp. 387–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Esteban, C. Nicolaus, A. Garmundi et al., “Effect of orally administered L-tryptophan on serotonin, melatonin, and the innate immune response in the rat,” Molecular and Cellular Biochemistry, vol. 267, no. 1-2, pp. 39–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Riemann, B. Feige, M. Hornyak, S. Koch, F. Hohagen, and U. Voderholzer, “The tryptophan depletion test: Impact on sleep in primary insomnia—a pilot study,” Psychiatry Research, vol. 109, no. 2, pp. 129–135, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Sarris and G. J. Byrne, “A systematic review of insomnia and complementary medicine,” Sleep Medicine Reviews, vol. 15, no. 2, pp. 99–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. E. Hartmann, J. G. Lindsley, and C. Spinweber, “Chronic insomnia: effects of tryptophan, flurazepam, secobarbital, and placebo,” Psychopharmacology, vol. 80, no. 2, pp. 138–142, 1983. View at Publisher · View at Google Scholar · View at Scopus
  52. K. Demisch, J. Bauer, and K. Georgi, “Treatment of severe chronic insomnia with L-tryptophan and varying sleeping times,” Pharmacopsychiatry, vol. 20, no. 6, pp. 245–248, 1987. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Hudson, S. P. Hudson, T. Hecht, and J. Mackenzie, “Protein source tryptophan versus pharmaceutical grade tryptophan as an efficacious treatment for chronic insomnia,” Nutritional Neuroscience, vol. 8, no. 2, pp. 121–127, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. U.S. Food and Drug Administration, “Information Paper of L-Typtophan and 5-hydroxy-L-tryptophan,” Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements, 2001, http://www.nemsn.org/Articles/FDA-Info.pdf.
  55. S. Shapiro, E. Kilbourne, M. Eidson, R. Philen, R. Voorhees, and C. M. Sewell, “L-tryptophan and eosinophilia-myalgia syndrome,” The Lancet, vol. 344, no. 8925, pp. 817–819, 1994. View at Publisher · View at Google Scholar · View at Scopus
  56. D. F. Grotenhermen, “Pharmacokinetics and pharmacodynamics of cannabinoids,” Clinical Pharmacokinetics, vol. 42, pp. 327–360, 2012. View at Publisher · View at Google Scholar
  57. U.S. Food and Drug Administration, Inter-Agency Advisory Regarding Claims That Smoked Marijuana Is a Medicine, 2014, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108643.htm.
  58. L. L. B. Ponto, “Challenges of marijuana research,” Brain, vol. 129, no. 5, pp. 1081–1083, 2006. View at Publisher · View at Google Scholar
  59. A. Kales, P. Goring, J. Hanley, M. Baker, N. Kanas, and W. Rickles, Effects of Marihuana Administration and Withdrawal in Chronic Users and Naive Subjects, Psychophysiology, Cambridge University Press, Cambridge, UK, 1972.
  60. F. R. Freemon, “The effect of chronically administered delta-9-tetrahydrocannabinol upon the polygraphically monitored sleep of normal volunteers,” Drug and Alcohol Dependence, vol. 10, no. 4, pp. 345–353, 1982. View at Publisher · View at Google Scholar · View at Scopus
  61. I. Karacan, A. Fernandez Salas, and W. J. Coggins, “Sleep electroencephalographic-electrooculographic characteristics of chronic marijuana users: part I,” Annals of the New York Academy of Sciences, vol. 282, pp. 348–374, 1976. View at Publisher · View at Google Scholar · View at Scopus
  62. I. Feinberg, R. Jones, J. M. Walker, C. Cavness, and J. March, “Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man,” Clinical Pharmacology and Therapeutics, vol. 17, no. 4, pp. 458–466, 1975. View at Google Scholar · View at Scopus
  63. A. N. Nicholson, C. Turner, B. M. Stone, and P. J. Robson, “Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults,” Journal of Clinical Psychopharmacology, vol. 24, no. 3, pp. 305–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. I. Feinberg, R. Jones, J. Walker, C. Cavness, and T. Floyd, “Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns,” Clinical Pharmacology and Therapeutics, vol. 19, no. 6, pp. 782–794, 1976. View at Google Scholar · View at Scopus
  65. G. M. Reisfield, A. D. Wasan, and R. N. Jamison, “The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature,” Pain Medicine, vol. 10, no. 8, pp. 1434–1441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. W. J. Maloney, “Significance of cannabis use to dental practice,” The Journal of the Michigan Dental Association, vol. 93, pp. 44–48, 2011. View at Google Scholar
  67. P. T. Reid, J. Macleod, and J. R. Robertson, “Cannabis and the lung,” The Journal of the Royal College of Physicians of Edinburgh, vol. 40, no. 4, pp. 328–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. P. J. Houghton, “The scientific basis for the reputed activity of valerian,” Journal of Pharmacy and Pharmacology, vol. 51, no. 5, pp. 505–512, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Hadley and J. J. Petry, “Valerian,” The American Family Physician, vol. 67, no. 8, pp. 1755–1758, 2003. View at Google Scholar · View at Scopus
  70. G. D. Anderson, G. W. Elmer, E. D. Kantor, I. E. Templeton, and M. V. Vitiello, “Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects,” Phytotherapy Research, vol. 19, no. 9, pp. 801–803, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. B. M. Dietz, G. B. Mahady, G. F. Pauli, and N. R. Farnsworth, “Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro,” Molecular Brain Research, vol. 138, no. 2, pp. 191–197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. C. E. Müller, B. Schumacher, A. Brattström, E. A. Abourashed, and U. Koetter, “Interactions of valerian extracts and a fixed valerian—hop extract combination with adenosine receptors,” Life Sciences, vol. 71, no. 16, pp. 1939–1949, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. M. O'Hara, “A review of 12 commonly used medicinal herbs,” Archives of Family Medicine, vol. 7, no. 6, pp. 523–536, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. Valerian Supplements Review, August 2014, https://www.consumerlab.com/reviews/valerian_supplements_review/valerian/.
  75. D. M. Taibi, C. A. Landis, H. Petry, and M. V. Vitiello, “A systematic review of valerian as a sleep aid: safe but not effective,” Sleep Medicine Reviews, vol. 11, no. 3, pp. 209–230, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. M. I. Fernández-San-Martín, R. Masa-Font, L. Palacios-Soler, P. Sancho-Gómez, C. Calbó-Caldentey, and G. Flores-Mateo, “Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials,” Sleep Medicine, vol. 11, no. 6, pp. 505–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. F. Donath, S. Quispe, K. Diefenbach, A. Maurer, I. Fietze, and I. Roots, “Critical evaluation of the effect of valerian extract on sleep structure and sleep quality,” Pharmacopsychiatry, vol. 33, no. 2, pp. 47–53, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Diaper and I. Hindmarch, “A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults,” Phytotherapy Research, vol. 18, no. 10, pp. 831–836, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. K. T. Hallam, J. S. Olver, C. McGrath, and T. R. Norman, “Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers,” Human Psychopharmacology: Clinical and Experimental, vol. 18, no. 8, pp. 619–625, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Salter and S. Brownie, “Treating primary insomnia: the efficacy of valerian and hops,” Australian family physician, vol. 39, no. 6, pp. 433–437, 2010. View at Google Scholar · View at Scopus
  81. S. Bent, A. Padula, D. Moore, M. Patterson, and W. Mehling, “Valerian for sleep: a systematic review and meta-analysis,” American Journal of Medicine, vol. 119, no. 12, pp. 1005–1012, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. A. D. Oxman, S. Flottorp, K. Håvelsrud et al., “A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia,” PLoS ONE, vol. 2, no. 10, Article ID e1040, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. S. M. Taavoni, N. B. Ekbatani, M. Kashaniyan, and H. M. Haghani, “Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial,” Menopause, vol. 18, no. 9, pp. 951–955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. N. Maroo, A. Hazra, and T. Das, “Efficacy and safety of a polyherbal sedative-hypnotic formulation NSF-3 in primary insomnia in comparison to zolpidem: a randomized controlled trial,” Indian Journal of Pharmacology, vol. 45, no. 1, pp. 34–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. NCCIH Funding: Appropriations History, 2015, http://nccih.nih.gov/about/budget/appropriations.htm.